Hansa Biopharma: Lower WACC Results in Reiterated Base Case - Redeye

Redeye returns with a comment after the conference call on the EUR115m licensing deal yesterday. We have updated our model with a lower WACC, thanks to the significantly reduced dilution risk, resulting in a restatement of our base case of SEK85, despite estimated lower peak sales in kidney transplantation and AMR.

Länk till analysen i sin helhet: https://www.redeye.se/research/1168056/hansa-biopharma-lower-wacc-results-in-reiterated-base-case?utm_source=finwire&utm_medium=RSS